Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutcs

Richard Platt, Robert Davis, Jonathan Finkelstein, Alan S. Go, Jerry H. Gurwitz, Douglas Roblin, Stephen Soumerai, Dennis Ross-Degnan, Susan Andrade, Michael J. Goodman, Brian Martinson, Marsha A. Raebel, David Smith, Marianne Ulcickas-Yood, K. Arnold Chan

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Research and education programs in therapeutics that combine the data, organizational capabilities, and expertise of several managed care organizations working in concert can serve an important role when a single organization is not large enough to address a question of interest, when diversity in populations or delivery systems is required, and when it is necessary to establish consistency of results in different settings. Nine members of the HMO Research Network, a consortium of health maintenance organizations (HMOs) that perform public domain research, have formed a Center for Education and Research on Therapeutics (CERT), sponsored by the Agency for Healthcare Research and Quality, to conduct multicenter research in therapeutics. The CERT uses a distributed organizational model with shared leadership, in which data reside at the originating organization until they are needed to support a specific study. Extraction of data from the host computer systems, and some manipulation of data, is typically accomplished through computer programs that are developed centrally, then modified for use at each site. For complex studies, pooled analysis files are created by a coordinating center, and then analysed by investigators throughout the HMOs. It is also possible to contact HMO members when necessary. This multicenter environment has several benefits, addressing: (1) a wide array of questions about the safety and effectiveness of therapeutics, (2) the impact of efforts to change clinicians' and patients' behavior, and (3) pharmacoeconomic and pharmacogenetic questions.

Original languageEnglish (US)
Pages (from-to)373-377
Number of pages5
JournalPharmacoepidemiology and Drug Safety
Volume10
Issue number5
DOIs
StatePublished - Dec 27 2001

Fingerprint

Health Maintenance Organizations
Health Services Research
Therapeutic Human Experimentation
Education
Organizations
Research
Organizational Models
Pharmaceutical Economics
Public Sector
Pharmacogenetics
Computer Systems
Managed Care Programs
Therapeutic Uses
Therapeutics
Software
Research Personnel
Safety
Population

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Pharmacology (medical)

Cite this

Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutcs. / Platt, Richard; Davis, Robert; Finkelstein, Jonathan; Go, Alan S.; Gurwitz, Jerry H.; Roblin, Douglas; Soumerai, Stephen; Ross-Degnan, Dennis; Andrade, Susan; Goodman, Michael J.; Martinson, Brian; Raebel, Marsha A.; Smith, David; Ulcickas-Yood, Marianne; Arnold Chan, K.

In: Pharmacoepidemiology and Drug Safety, Vol. 10, No. 5, 27.12.2001, p. 373-377.

Research output: Contribution to journalArticle

Platt, R, Davis, R, Finkelstein, J, Go, AS, Gurwitz, JH, Roblin, D, Soumerai, S, Ross-Degnan, D, Andrade, S, Goodman, MJ, Martinson, B, Raebel, MA, Smith, D, Ulcickas-Yood, M & Arnold Chan, K 2001, 'Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutcs', Pharmacoepidemiology and Drug Safety, vol. 10, no. 5, pp. 373-377. https://doi.org/10.1002/pds.607
Platt, Richard ; Davis, Robert ; Finkelstein, Jonathan ; Go, Alan S. ; Gurwitz, Jerry H. ; Roblin, Douglas ; Soumerai, Stephen ; Ross-Degnan, Dennis ; Andrade, Susan ; Goodman, Michael J. ; Martinson, Brian ; Raebel, Marsha A. ; Smith, David ; Ulcickas-Yood, Marianne ; Arnold Chan, K. / Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutcs. In: Pharmacoepidemiology and Drug Safety. 2001 ; Vol. 10, No. 5. pp. 373-377.
@article{f35a1158c910436f93472d0abdb0ea17,
title = "Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutcs",
abstract = "Research and education programs in therapeutics that combine the data, organizational capabilities, and expertise of several managed care organizations working in concert can serve an important role when a single organization is not large enough to address a question of interest, when diversity in populations or delivery systems is required, and when it is necessary to establish consistency of results in different settings. Nine members of the HMO Research Network, a consortium of health maintenance organizations (HMOs) that perform public domain research, have formed a Center for Education and Research on Therapeutics (CERT), sponsored by the Agency for Healthcare Research and Quality, to conduct multicenter research in therapeutics. The CERT uses a distributed organizational model with shared leadership, in which data reside at the originating organization until they are needed to support a specific study. Extraction of data from the host computer systems, and some manipulation of data, is typically accomplished through computer programs that are developed centrally, then modified for use at each site. For complex studies, pooled analysis files are created by a coordinating center, and then analysed by investigators throughout the HMOs. It is also possible to contact HMO members when necessary. This multicenter environment has several benefits, addressing: (1) a wide array of questions about the safety and effectiveness of therapeutics, (2) the impact of efforts to change clinicians' and patients' behavior, and (3) pharmacoeconomic and pharmacogenetic questions.",
author = "Richard Platt and Robert Davis and Jonathan Finkelstein and Go, {Alan S.} and Gurwitz, {Jerry H.} and Douglas Roblin and Stephen Soumerai and Dennis Ross-Degnan and Susan Andrade and Goodman, {Michael J.} and Brian Martinson and Raebel, {Marsha A.} and David Smith and Marianne Ulcickas-Yood and {Arnold Chan}, K.",
year = "2001",
month = "12",
day = "27",
doi = "10.1002/pds.607",
language = "English (US)",
volume = "10",
pages = "373--377",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutcs

AU - Platt, Richard

AU - Davis, Robert

AU - Finkelstein, Jonathan

AU - Go, Alan S.

AU - Gurwitz, Jerry H.

AU - Roblin, Douglas

AU - Soumerai, Stephen

AU - Ross-Degnan, Dennis

AU - Andrade, Susan

AU - Goodman, Michael J.

AU - Martinson, Brian

AU - Raebel, Marsha A.

AU - Smith, David

AU - Ulcickas-Yood, Marianne

AU - Arnold Chan, K.

PY - 2001/12/27

Y1 - 2001/12/27

N2 - Research and education programs in therapeutics that combine the data, organizational capabilities, and expertise of several managed care organizations working in concert can serve an important role when a single organization is not large enough to address a question of interest, when diversity in populations or delivery systems is required, and when it is necessary to establish consistency of results in different settings. Nine members of the HMO Research Network, a consortium of health maintenance organizations (HMOs) that perform public domain research, have formed a Center for Education and Research on Therapeutics (CERT), sponsored by the Agency for Healthcare Research and Quality, to conduct multicenter research in therapeutics. The CERT uses a distributed organizational model with shared leadership, in which data reside at the originating organization until they are needed to support a specific study. Extraction of data from the host computer systems, and some manipulation of data, is typically accomplished through computer programs that are developed centrally, then modified for use at each site. For complex studies, pooled analysis files are created by a coordinating center, and then analysed by investigators throughout the HMOs. It is also possible to contact HMO members when necessary. This multicenter environment has several benefits, addressing: (1) a wide array of questions about the safety and effectiveness of therapeutics, (2) the impact of efforts to change clinicians' and patients' behavior, and (3) pharmacoeconomic and pharmacogenetic questions.

AB - Research and education programs in therapeutics that combine the data, organizational capabilities, and expertise of several managed care organizations working in concert can serve an important role when a single organization is not large enough to address a question of interest, when diversity in populations or delivery systems is required, and when it is necessary to establish consistency of results in different settings. Nine members of the HMO Research Network, a consortium of health maintenance organizations (HMOs) that perform public domain research, have formed a Center for Education and Research on Therapeutics (CERT), sponsored by the Agency for Healthcare Research and Quality, to conduct multicenter research in therapeutics. The CERT uses a distributed organizational model with shared leadership, in which data reside at the originating organization until they are needed to support a specific study. Extraction of data from the host computer systems, and some manipulation of data, is typically accomplished through computer programs that are developed centrally, then modified for use at each site. For complex studies, pooled analysis files are created by a coordinating center, and then analysed by investigators throughout the HMOs. It is also possible to contact HMO members when necessary. This multicenter environment has several benefits, addressing: (1) a wide array of questions about the safety and effectiveness of therapeutics, (2) the impact of efforts to change clinicians' and patients' behavior, and (3) pharmacoeconomic and pharmacogenetic questions.

UR - http://www.scopus.com/inward/record.url?scp=0035211437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035211437&partnerID=8YFLogxK

U2 - 10.1002/pds.607

DO - 10.1002/pds.607

M3 - Article

VL - 10

SP - 373

EP - 377

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 5

ER -